Novartis reported strong Q2 2026 results with $14.41B sales and a core profit beat, driven by Kisqali (+43%) and Scemblix. Full-year guidance reaffirmed despite Entresto patent cliff.
GLP-1 drugs and insurance uncertainty weigh on demand.
Abbott delivered robust Q2 2026 earnings driven by 42% growth in its Diagnostics segment, led by strong Cologuard adoption.
Strong cost control and Optum performance drive recovery.
The company raised full-year guidance and remains on track for its first $100 billion revenue year.
Despite beating Q2 estimates and lifting 2026 guidance, Elevance Health saw margins compress sharply. Core operating margin fell to 3.5% on higher medical costs.
